Ranbaxy To Buy U.S. FDA-Approved Plants Outside Of India
This article was originally published in PharmAsia News
Executive Summary
Hampered by the U.S. FDA's rejection of 30 of its generic drugs because of two plants in which they were made, Ranbaxy Laboratories now plans to buy plants that already have the agency's approval. The plants have not been identified, but they could be in the United States or in other countries so the Indian drug maker can get its products back on the market, according to CEO Malvinder Singh. He said he expected to select the facilities by the end of the year, although production would be more expensive than at Ranbaxy's own Indian facilities. (Click here for more